EI
CHRS icon

EAM Investors’s Coherus Oncology CHRS Stock Holding History

EAM Investors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-309,801
Closed -$524K – 288
2026
Q1 		$524K Buy
+309,801
New +$550K 0.06% 261
2019
Q3 		– Sell
-66,041
Closed -$1.46M – 246
2019
Q2 		$1.46M Buy
+66,041
New +$1.15M 0.36% 130
2017
Q1 		– Sell
-24,652
Closed -$694K – 319
2016
Q4 		$694K Sell
24,652
-13,750
-36% -$385K 0.09% 290
2016
Q3 		$1.03M Buy
+38,402
New +$1.05M 0.14% 249
2015
Q4 		– Sell
-35,656
Closed -$715K – 315
2015
Q3 		$715K Buy
+35,656
New +$1.08M 0.11% 284
2015
Q2 		– Sell
-162,485
Closed -$4.97M – 327
2015
Q1 		$4.97M Buy
+162,485
New +$4.2M 0.57% 18

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

EAM Investors's CHRS Position: Q2 2026 in Review

EAM Investors sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 309,801 shares — an estimated $524K sold.

EAM Investors first reported a position in CHRS in Q1 2015 and held it in 6 quarters. The position peaked at $4.97M in Q1 2015. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • EAM Investors reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 309,801 Coherus Oncology shares in Q2 2026, an estimated $524K.
  • EAM Investors first reported a position in Coherus Oncology in Q1 2015 and held it in 6 quarters.
  • EAM Investors's Coherus Oncology position peaked at $4.97M in Q1 2015.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.